RedHill: Oral Broad-Acting Antivirals Inhibit Dominant Omicron Sub-Variant BA.5
- RedHill Biopharma Ltd announced study results showing in vitro efficacy against the currently dominant omicron COVID-19 sub-variant BA.5, by both RedHill's broad-acting investigational antivirals once-daily RHB-107 (upamostat) and twice-daily opaganib.
- These results build on previously reported data on the inhibition of COVID-19, variants of concern, and other viruses and further support their broad-acting, host-directed mechanisms of action.
- RHB-107 recently reported positive results from the Phase 2 part of Phase 2/3 study in symptomatic non-hospitalized COVID-19, showing good safety and tolerability and highly promising efficacy results, including faster recovery from severe COVID-19 symptoms and reduced rates of hospitalization.
- Opaganib has previously demonstrated a 70% reduction in mortality in key hospitalized patient sub-populations, improved viral RNA clearance, and faster time to recovery in its Phase 3 study in hospitalized patients with moderate to severe COVID-19.
- Late-stage development of both opaganib and RHB-107 is ongoing pending Phase 3 trial design regulatory approvals and securing of external funding.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.